CLINUVEL Expands Pharmaceutical Portfolio
07 nov. 2021 23h03 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Nov. 08, 2021 (GLOBE NEWSWIRE) -- CLINUVEL has expanded its pharmaceutical development portfolio with NEURACTHEL®, novel formulations of the melanocortin adrenocorticotropic...
CLINUVEL expands DNA Repair Program
23 mars 2021 20h10 HE
|
Clinuvel Pharmaceuticals Limited
SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) MELBOURNE, Australia, March 24, 2021 (GLOBE NEWSWIRE) -- CLINUVEL has expanded its clinical program to...
CLINUVEL to Trial Innovative Drug in Stroke
27 oct. 2020 18h50 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The drug afamelanotide will be used for the first time in patients with acute stroke. The study will evaluate the safety and efficacy of...
First patient dosed in SCENESSE® DNA Repair Program
15 sept. 2020 03h31 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment Note to editors: CLINUVEL is releasing in-depth infographics and a video...
CLINUVEL progresses innovative DNA Repair Program
10 sept. 2020 03h18 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 10, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced the progression of its drug SCENESSE® (afamelanotide 16mg) to treat the disease xeroderma...
CLINUVEL Opens VALLAURIX R&D Centre In Singapore
31 août 2020 05h35 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and SINGAPORE, Aug. 31, 2020 (GLOBE NEWSWIRE) -- The CLINUVEL Group today announced the opening of its state-of-the-art centralised Research & Development Centre in...
PRÉNUMBRA® - CLINUVEL's Second Afamelanotide Formulation
13 juil. 2020 03h38 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and SINGAPORE, July 13, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS today revealed PRÉNUMBRA®, the Company’s second afamelanotide product in development. PRÉNUMBRA® is a...
SCENESSE® to be Prescribed in China
23 avr. 2020 02h08 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and HANGZHOU, China, April 23, 2020 (GLOBE NEWSWIRE) -- Australian-based company CLINUVEL is launching SCENESSE® (afamelanotide 16mg) in the People’s Republic of China for the...
Innovative drug launched for rare, isolating, “light intolerance” disorder
16 avr. 2020 02h53 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and MENLO PARK, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Americans living with a rare genetic disorder that forces them to choose between self-isolation in the dark, or...
FDA Approves SCENESSE® For Genetic Disorder
08 oct. 2019 19h11 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- The US Food and Drug Administration (FDA) has approved a new drug as the first ever treatment for a rare genetic metabolic disorder which...